The effects of isotretinoin therapy on the biliary system

Abstract

The aim of the present study was to investigate the potential effects of isotretinoin on the biliary system in patients with acne vulgaris receiving isotretinoin therapy. This was a preliminary retrospective study involving 40 patients with severe acne vulgaris who attended the dermatology clinic and were administered different doses (20 or 30 mg/day) of isotretinoin. Serum levels of AST, ALT, ALP, GGT, total bilirubin, direct bilirubin, and indirect bilirubin at the beginning and at the first month of therapy were scanned, recorded, and statistically analyzed. Total and indirect bilirubin levels at the first month of treatment in 30 patients, receiving isotretinoin at a dose of 20 mg/day, were significantly lower compared to the baseline values (p = .02 and p = .03, respectively), whereas AST and GGT serum levels were significantly higher (p = .003 and p = .006 respectively). No significant reduction in total and indirect bilirubin levels was detectable at the first month of treatment in 10 patients receiving isotretinoin at a dose of 30 mg/day; however, AST, ALP, and GGT levels were significantly elevated in these patients (p = .023; p = .004; and p = .001, respectively). To our knowledge, there is no previous study investigating the effects of isotretinoin on the biliary system, and, therefore, the present study is a preliminary one. Our findings implicate that low dose (20 mg/day) isotretinoin therapy can potentially reduce total and indirect bilirubin levels. Long‐term, large‐scale, prospective studies with patients receiving different doses of isotretinoin may provide more reliable information regarding the bilirubin lowering effects of isotretinoin and optimum dosing for achieving this clinical effect.

Low dose of isotretinoin: A comprehensive review

“…A statistically significant elevation in serum aspartate aminotransferase (AST), alkaline phosphatase, and gamma‐glutamyl transferase (GGT) values was striking in patients receiving isotretinoin at a dose of 30 mg/day. Significant rise in AST and GGT serum levels was prominent even in the lower 20 mg/day dose group was also noted (Saylam Kurtipek et al, ). In a retrospective study, the authors noted that liver function test alterations isotretinoin usage, in most of the cases, were mild, transient, and stable even when maintaining the same dose of isotretinoin (Pona et al, ).…”